title: Determinants of 6-month survival of critically ill patients with an active hematologic malignancy.
abstract: This study assessed the determinants of 6-month survival of critically ill patients with an active hematologic malignancy (HM).
  
  
  
  All patients with an active HM defined by either receiving ongoing or due to receive antineoplastic therapy, admitted to 2 tertiary intensive care units between 2010 and 2015, were included in this retrospective cohort study.
  
  
  
  Of the 273 patients included in the study (median age, 63[interquartile range, 54-71] years; 40.7% female), 116 (42.5%; 95% confidence interval, 36.8-48.4) died in hospital. The 6-month mortality was 56.4% (95% confidence interval, 50.5-62.2). Mechanical ventilation, intensive care unit admission source, and the type of active HM were significantly associated with hospital mortality and 6-month survival, after adjusting for severity of acute illness. The type of active HM was the most important prognostic factor, with over a 10-fold difference in 6-month survival between HM with the best and worst prognosis. In addition, recent hematopoietic stem cell transplant (<30 days) was associated with a better 6-month survival.
  
  
  
  Differences in 6-month survival between critically ill patients with different types of active HM were substantial. Recent hematopoietic stem cell transplant, severity of illness, and use of mechanical ventilation were additional important determinants of 6-month survival in patients with an active HM.
authors.affiliation: Department of Intensive Care, Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia 6009, Australia. Electronic address: Stephen.Richards@health.wa.gov.au.
authors.forename: Stephen
authors.initials: S
authors.lastname: Richards
authors.affiliation: Department of Intensive Care, Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia 6009, Australia. Electronic address: Bradley.Wibrow@health.wa.gov.au.
authors.forename: Bradley
authors.initials: B
authors.lastname: Wibrow
authors.affiliation: Department of Intensive Care, Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia 6009, Australia. Electronic address: Matthew.Anstey@health.wa.gov.au.
authors.forename: Matthew
authors.initials: M
authors.lastname: Anstey
authors.affiliation: Department of Intensive Care, Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia 6009, Australia. Electronic address: Hasib.Sidiqi@health.wa.gov.au.
authors.forename: Hasib
authors.initials: H
authors.lastname: Sidiqi
authors.affiliation: Department of Intensive Care, Royal Perth Hospital, Perth, Western Australia 6847, Australia. Electronic address: Ashlyn.Chee@health.wa.gov.au.
authors.forename: Ashlyn
authors.initials: A
authors.lastname: Chee
authors.affiliation: Department of Intensive Care, Royal Perth Hospital, Perth, Western Australia 6847, Australia. Electronic address: Kwok.Ho@health.wa.gov.au.
authors.forename: Kwok M
authors.initials: KM
authors.lastname: Ho
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016638:Critical Illness / Q000401:mortality / Q000628:therapy*; D016208:Databases, Factual; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D017052:Hospital Mortality; D006760:Hospitalization; D006801:Humans; D007362:Intensive Care Units; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012121:Respiration, Artificial / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015996:Survival Rate; D014904:Western Australia
chemical_list: D000970:Antineoplastic Agents
keywords: Critical care; Hematologic malignancy; Intensive care